查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1916947

SGLT2抑制剂治疗市场按产品类型、适应症、规格、通路和最终用户划分－全球预测（2026-2032年）

SGLT2 Inhibitors Treatment Market by Product Type, Indication, Strength, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

SGLT2抑制剂治疗市场预计到2025年将达到176.5亿美元，到2026年将成长到189.6亿美元，到2032年将达到323.5亿美元，年复合成长率为9.03%。

主要市场统计数据
基准年 2025 176.5亿美元
预计年份：2026年 189.6亿美元
预测年份：2032年 323.5亿美元
复合年增长率 (%) 9.03%

权威解读SGLT2抑制剂疗法：整合临床进展、跨专科应用、治疗管道以及对相关人员的策略意义

SGLT2抑制剂已从最初局限于降血糖的药物发展成为影响心血管代谢和肾臟疾病整体的多效疗法。本文概述了这些药物的治疗、临床和商业性背景，整合了最新的临床证据、指南更新以及影响处方和用药的医疗服务模式变革。说明将重点介绍其除血糖控制之外的其他作用机制，并探讨这些益处如何重塑临床应用、药物推广和相关人员的期望。

全面探讨不断扩大的证据、不断发展的指南以及医疗保健服务领域的创新如何从根本上重塑SGLT2抑制剂的采用和获取。

由于临床证据、指引更新和创新医疗模式的融合，SGLT2抑制剂的治疗格局正在经历变革性变化。过去几年，随机试验和真实世界数据分析拓展了这类药物的适应症，指南专家小组也提供了全面的建议，认可了它们在血糖控制之外，对心臟衰竭和肾臟保护的益处。因此，治疗策略正从以糖尿病为中心的方法转变为整合心血管代谢和肾功能的综合策略。

对2025年关税调整对SGLT2治疗药物供应链决策、采购经济效益与合约策略的影响进行务实分析

预计2025年贸易政策调整和关税波动将为SGLT2抑制剂分销和采购相关相关人员带来更多复杂性。进口关税和供应链相关课税的变化可能会影响成品药和活性药物成分的到岸成本，促使经销商和医疗保健系统重新评估合约策略、定价模式和库存计划。其影响不仅限于单位成本，还会影响跨境采购决策以及拥有不同生产基地的製造商之间的竞争。

将分子特异性特征、治疗适应症、分销管道、终端用户环境和剂量强度与差异化的临床和商业性需求联繫起来的详细細項分析

本文建构了一个针对SGLT2抑制剂的详细细分框架，重点分析了临床效益、用药障碍和商业性机会之间的交集。按产品类型划分，该治疗领域包含不同的分子——Canagliflozin、Dapagliflozin、恩格Empagliflozin和艾格列净——每种分子都有其特定的循证依据、安全性特征和品牌历史，这些因素会影响配药师的选择以及药物在药品目录中的排名。依适应症检验趋势发现，慢性肾臟病、心臟衰竭和第2型糖尿病的需求模式各不相同。在这些领域内，实证医学证据的强度和指南推荐决定了专科医生和全科医生采用该药物的优先顺序。

策略性区域观点揭示了美洲、欧洲、中东和非洲以及亚太地区的医疗保健生态系统如何以不同的方式推动SGLT2抑制剂疗法的采用、取得和报销趋势。

区域差异影响SGLT2抑制剂计画的临床应用模式、报销架构和策略重点。美洲地区的医疗保健体係由公私混合支付，深受管理式医疗处方笺以及以结果为导向、以以金额为准的心臟衰竭和肾臟病预防合约试点计画的影响。这种环境鼓励强有力的卫生经济学证据和以支付观点的价值提案，区域卓越中心主导SGLT2抑制剂的应用，并将指南转化为实践。

重点评估竞争定位、策略联盟和基于证据的差异化策略，这些策略将决定SGLT2抑制剂赞助商的商业性成功。

创新品牌与新进者之间的竞争体现在临床差异化、实证投入以及与整个医疗生态系统的策略伙伴关係。领先的专有分子凭藉可靠的心血管和肾臟疗效数据、已获得的临床医生认可以及广泛的药品目录覆盖，继续在各个细分市场占据主导地位。同时，处于研发管线的参与企业和后期製剂正透过专注于拓展适应症、提升安全性或开发新型给药方式，开闢独特的临床市场。

为行业领导者提供切实可行的高影响力建议，以整合临床证据、支付方参与、分销韧性和跨部门商业化，从而实现可持续的医疗服务可及性。

产业领导者应采取多管齐下的方法，整合证据产生、相关人员和营运准备，以加速推广应用并实现永续的医疗服务取得。首先，应优先进行跨适应症的证据项目，这些项目应涵盖心臟病学和肾臟病学终点以及血糖控制结果，从而产生支付方和专科医学协会扩展指南所需的数据。其次，应投资于支付方价值评估文件和真实世界结果研究，以量化风险分担机制相关事件的临床意义显着的减少。

我们采用透明、三角验证的调查方法，结合临床文献、指引分析、相关人员访谈和情境测试，以得出可操作的实证结论。

本分析的调查方法采用三角测量法，整合了同侪审查的临床文献、指南声明、支付方政策文件以及利害关係人的定性回馈。主要研究包括对循环系统、肾臟病学和基层医疗领域的临床医生，以及医院药房主任和专科药房负责人进行结构化访谈，以了解实际治疗启动途径、依从性障碍和处方集决策标准。这些发现得到了利用临床日记、安全资讯和专业学会文件的二次研究的支持。

一份简明扼要的综合报告，清楚阐述了临床扩展、准入需求、SGLT2抑制剂应用以及营运重点等因素对患者持续获益的策略影响。

总之，SGLT2抑制剂代表了一种变革时期的治疗药物类别，其作用已从血糖控制扩展到更广泛的实证心血管和肾臟疾病治疗。随着这一发展进程的不断推进，相关人员需要调整其临床管道、支付方价值提案和营运策略，以反映多学科影响和不断变化的医疗服务获取环境。展望未来，临床应用将越来越依赖可靠的真实世界数据、与之相符的支付方价值提案以及支持治疗启动、后续观察和患者依从性的整合式医疗模式。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. SGLT2抑制剂治疗市场（依产品类型划分）

  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • 艾格列净

9. SGLT2抑制剂治疗市场（依适应症划分）

  • 慢性肾臟病
  • 心臟衰竭
  • 2型糖尿病

10. SGLT2抑制剂治疗市场（依强度划分）

  • 10mg
  • 25mg

11. SGLT2抑制剂治疗市场依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

12. SGLT2抑制剂治疗市场（依最终用户划分）

  • 诊所
  • 居家护理患者
  • 医院

13. SGLT2抑制剂治疗市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 SGLT2抑制剂治疗市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国SGLT2抑制剂治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国SGLT2抑制剂治疗市场

第十七章：中国SGLT2抑制剂治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-AE420CB15411

The SGLT2 Inhibitors Treatment Market was valued at USD 17.65 billion in 2025 and is projected to grow to USD 18.96 billion in 2026, with a CAGR of 9.03%, reaching USD 32.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.65 billion
Estimated Year [2026] USD 18.96 billion
Forecast Year [2032] USD 32.35 billion
CAGR (%) 9.03%

An authoritative orientation to SGLT2 inhibitor therapeutics synthesizing clinical evolution, cross-specialty adoption, and the strategic implications for care pathways and stakeholders

SGLT2 inhibitors have transitioned from a narrowly defined glucose-lowering option to a multifaceted therapeutic class with implications across cardiometabolic and renal care. This introduction frames the therapeutic, clinical, and commercial context for these agents by synthesizing recent clinical evidence, guideline evolution, and care delivery changes that influence prescribing and access. The narrative that follows emphasizes the mechanism-driven benefits that extend beyond glycemic control and discusses how those benefits are reshaping clinical pathways, formulary conversations, and stakeholder expectations.

Importantly, the introduction positions SGLT2 inhibitors as interventions whose value proposition is being continuously refined through post-approval data and health-system implementation efforts. It highlights how cardiology, nephrology, and primary care adoption trajectories are being influenced by new endpoints, safety data, and payer criteria. In doing so, readers will gain a compact but deep orientation to the therapeutic class, the principal drivers that are altering utilization patterns, and the strategic considerations that organizations must address to maintain competitiveness and clinical relevance.

A comprehensive exploration of how evidence expansion, guideline evolution, and care delivery innovation are fundamentally reshaping SGLT2 inhibitor adoption and access

The landscape for SGLT2 inhibitor treatment is undergoing transformative shifts driven by convergence of clinical evidence, guideline updates, and care model innovations. Over the past several years, randomized trials and real-world analyses have broadened the indications for the class, prompting guideline committees to issue more inclusive recommendations that recognize benefits in heart failure and renal protection in addition to glycemic control. Consequently, therapeutic positioning is evolving from a diabetes-centered approach to an integrated cardiometabolic and renal strategy.

Concurrently, payers and health systems are modifying coverage frameworks to reflect outcomes-based value, which has accelerated adoption in specialty clinics and multidisciplinary programs. Pharmacoeconomic analyses and value dossiers are now essential components of market access strategies, and manufacturers are adapting their evidence-generation plans to support these narratives. In parallel, clinical practice is shifting toward earlier combination therapy and cross-specialty prescribing, with cardiologists and nephrologists increasingly initiating SGLT2 inhibitors independently of endocrinologists.

Moreover, advances in digital health and remote monitoring are altering adherence support and patient selection, enabling clinicians to identify candidates with high incremental benefit and to follow safety parameters more closely. As a result, commercial teams must realign segmentation, messaging, and clinical engagement to reflect a more heterogeneous prescriber base and to support multidisciplinary pathways. Taken together, these trends represent a structural change in how the class is perceived, adopted, and reimbursed across care settings, creating new windows for differentiation and partnership across the value chain.

A pragmatic analysis of how adjustments to United States tariff policy in 2025 could influence supply chain decisions, procurement economics, and contractual strategies for SGLT2 treatments

Anticipated trade policy adjustments and tariff shifts in the United States for 2025 introduce another layer of complexity for stakeholders involved in SGLT2 inhibitor distribution and procurement. Changes in import duties and supply-chain levies can affect the landed cost of finished formulations and active pharmaceutical ingredients, which in turn may prompt revisions to contracting strategies, pricing models, and inventory planning across distributors and health systems. The implications extend beyond unit costs to encompass cross-border sourcing decisions and the relative competitiveness of manufacturers with different production footprints.

Supply chain resilience therefore becomes a strategic priority, with organizations evaluating nearshoring, multiple-sourcing, and inventory buffering as mitigations against tariff-driven cost volatility. Payers and integrated delivery networks may respond by tightening formulary controls or by negotiating longer-term agreements that buffer against abrupt price movements. At the same time, manufacturers with diversified manufacturing and distribution capabilities will be better positioned to absorb incremental tariff effects or to re-route logistics to preserve price competitiveness.

Clinicians and procurement leaders should anticipate that procurement cycles may incorporate greater sensitivity to total cost of ownership considerations, including tariff exposure, freight variability, and storage requirements. Consequently, commercial teams need to prepare scenario-based contracting templates and to quantify the operational impact of tariff permutations on supply continuity and gross-to-net economics. In short, tariff dynamics are likely to influence commercial levers and operational decisions across the SGLT2 ecosystem, reinforcing the need for proactive risk management and cross-functional alignment.

In-depth segmentation insights tying molecule-specific profiles, therapeutic indications, distribution channels, end-user settings, and dose strength to differentiated clinical and commercial imperatives

A granular segmentation framework clarifies where clinical benefit, access friction, and commercial opportunity intersect for SGLT2 inhibitors. Based on product type, the therapeutic landscape is characterized by distinct molecules such as Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin, each of which has specific evidence bases, safety profiles, and brand histories that influence prescriber preference and formulary positioning. Examining indication-driven dynamics reveals differentiated demand patterns across Chronic Kidney Disease, Heart Failure, and Type 2 Diabetes, where evidence strength and guideline endorsements determine the priority of uptake within specialist groups and general practice.

Distribution channel considerations matter significantly for patient access and adherence, with hospital pharmacies often acting as points of initiation for in-hospital starts, online pharmacies providing convenience and continuity for maintenance therapy, and retail pharmacies serving as the predominant refilling touchpoint and a locus for patient counseling. End-user segmentation further sharpens operational and messaging requirements: clinics require streamlined initiation pathways and clinical decision support; homecare patients need clear remote-monitoring protocols and adherence interventions; and hospitals demand alignment with inpatient formularies and discharge planning processes. Strength differentiation, specifically 10 mg and 25 mg formulations, influences prescribing patterns based on renal function considerations, titration strategies, and co-prescribing with other cardiometabolic agents.

Integrating these segmentation lenses enables a more precise understanding of where to prioritize evidence generation, commercial resource allocation, and clinical outreach. It also highlights the need for tailored messaging that addresses the unique decision drivers of each prescriber type, distribution partner, and patient cohort, supporting interventions that improve initiation, persistence, and outcomes across the continuum of care.

Strategic regional perspectives articulating how Americas, Europe Middle East & Africa, and Asia-Pacific healthcare ecosystems drive distinct adoption, access, and reimbursement dynamics for SGLT2 therapies

Regional heterogeneity shapes clinical adoption patterns, reimbursement frameworks, and strategic priorities for SGLT2 inhibitor programs. In the Americas, care delivery is characterized by a mix of private and public payers, with strong influence from managed-care formularies and value-based contracting pilots that emphasize outcomes in heart failure and renal disease prevention. This environment incentivizes robust health-economic evidence and payer-focused value narratives, while regional centers of excellence lead adoption and guideline translation into practice.

Across Europe, the Middle East & Africa, regulatory and reimbursement landscapes vary widely, with national health technology assessment bodies and regional procurement consortia playing decisive roles. In these settings, early generation cost-effectiveness studies and real-world evidence demonstrating renal and cardiovascular benefits are critical for securing favorable coverage and inclusion on national formularies. Meanwhile, some markets in the region are showing accelerated adoption through specialist networks and integrated care pathways that prioritize the prevention of hospitalizations and progression to end-stage organ disease.

The Asia-Pacific region presents a mosaic of healthcare systems, ranging from high-resource markets with established specialist engagement to emerging markets where access and affordability remain central constraints. In this region, local clinical guideline adaptation, pricing policies, and availability of biosimilar-like alternatives or locally produced generics will influence the pace and pattern of uptake. Across all regions, cross-border evidence-sharing, multinational payer pilots, and collaborative care models serve as accelerants for broader adoption, but localized strategies remain essential to navigate varying clinical priorities and reimbursement mechanisms.

A focused evaluation of competitive positioning, strategic alliances, and evidence-driven differentiation tactics that determine commercial success for SGLT2 inhibitor sponsors

Competitive dynamics among originator brands and newer entrants are defined by clinical differentiation, evidence investment, and strategic partnerships across the healthcare ecosystem. Leading proprietary molecules retain advantages where robust cardiovascular and renal outcome data exist alongside established clinician familiarity and broad formulary presence. Meanwhile, pipeline entrants and later-stage formulations focus on indication expansion, improved safety signals, or novel delivery modalities to carve out distinct clinical niches.

Partnerships with specialty pharmacies, integrated delivery networks, and digital therapeutics vendors are increasingly common as companies seek to embed their therapies into care pathways and adherence programs. Additionally, strategic collaborations with academic centers and professional societies to sponsor guideline-driven research and real-world evidence studies help to accelerate acceptance among non-specialist prescribers. Manufacturers are also exploring innovative contracting approaches that tie reimbursement to clinical outcomes or episode-of-care metrics, thereby aligning commercial incentives with payer priorities.

For commercial teams, the competitive imperative is to translate clinical differentiation into accessible value propositions for payers and clinicians while ensuring operational excellence in supply, patient support, and educational outreach. Organizations that combine strong evidence planning with pragmatic channel strategies and partnerships will be best positioned to influence prescribing behavior and maintain resilient access across a shifting reimbursement landscape.

High-impact, actionable recommendations for industry leaders to align clinical evidence, payer engagement, distribution resilience, and cross-functional commercialization for durable access

Industry leaders should adopt a multi-dimensional approach that aligns evidence generation, stakeholder engagement, and operational readiness to accelerate adoption and enable sustainable access. First, prioritize cross-indication evidence programs that address cardiology and nephrology endpoints in addition to glycemic outcomes, thereby generating the data payers and specialty societies require for broader guideline inclusion. Second, invest in payer-facing value dossiers and real-world outcome studies that quantify reduction in clinically meaningful events relevant to risk-sharing arrangements.

Third, develop differentiated channel strategies that support initiation in hospitals and clinics, continuity through retail and online pharmacies, and adherence via homecare support programs. This requires coordinated investments in digital adherence tools, nurse-led initiation pathways, and education for non-endocrinology prescribers. Fourth, prepare for tariff and supply-chain variability by diversifying sourcing, negotiating flexible contracting clauses, and creating scenario-based contingency plans to ensure uninterrupted supply.

Fifth, establish collaborative partnerships with specialty societies, patient advocacy organizations, and care delivery innovators to co-create guideline implementation tools and patient identification algorithms. Finally, implement cross-functional commercialization teams that integrate medical affairs, market access, and field commercial units to respond rapidly to evolving evidence and payer decisions. By executing these actions in parallel, leaders can convert clinical advantage into durable access and improved patient outcomes.

A transparent and triangulated research methodology combining clinical literature, guideline analysis, stakeholder interviews, and scenario testing to produce actionable, evidence-based insights

The research methodology underpinning this analysis integrates a triangulated approach that synthesizes peer-reviewed clinical literature, guideline statements, payer policy documents, and qualitative stakeholder input. Primary research included structured interviews with clinicians across cardiology, nephrology, and primary care, as well as with hospital pharmacy directors and specialty pharmacy leaders to capture real-world initiation pathways, adherence barriers, and formulary decision criteria. These insights were corroborated with secondary research drawing on clinical trial publications, safety communications, and professional society materials.

Data synthesis emphasized thematic convergence and cross-validation across information sources to identify robust patterns in prescribing behavior, payer responses, and operational constraints. Scenario planning and sensitivity analyses were employed to test the resilience of strategic recommendations against plausible changes in trade policy, reimbursement rules, and supply-chain disruptions. Throughout the methodology, transparency was maintained around inclusion criteria, source provenance, and the limitations of available data, ensuring that conclusions are grounded in verifiable evidence and expert interpretation rather than extrapolative forecasting.

A concise synthesis articulating the strategic consequences of clinical expansion, access imperatives, and operational priorities shaping SGLT2 inhibitor adoption and sustained patient benefit

In conclusion, SGLT2 inhibitors represent a therapeutic class in transition: their role has expanded from glycemic management to a broader, evidence-based contribution to cardiovascular and renal care. This evolution demands that stakeholders recalibrate clinical pathways, payer value narratives, and operational strategies to reflect the multi-specialty nature of benefit and the shifting landscape of access. Clinical adoption will increasingly depend on robust real-world evidence, payer-aligned value propositions, and integrated care models that support initiation, monitoring, and persistence.

Operationally, supply-chain resilience and proactive contracting will be necessary to manage external pressures such as tariff changes and logistical disruption. Commercial success will hinge on the ability to translate differentiated clinical evidence into tailored value stories for distinct prescriber groups and distribution channels, while maintaining alignment with payer expectations for outcomes and cost-effectiveness. By synthesizing clinical insight with pragmatic commercial planning, stakeholders can accelerate meaningful patient access and improve outcomes across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. SGLT2 Inhibitors Treatment Market, by Product Type

  • 8.1. Canagliflozin
  • 8.2. Dapagliflozin
  • 8.3. Empagliflozin
  • 8.4. Ertugliflozin

9. SGLT2 Inhibitors Treatment Market, by Indication

  • 9.1. Chronic Kidney Disease
  • 9.2. Heart Failure
  • 9.3. Type 2 Diabetes

10. SGLT2 Inhibitors Treatment Market, by Strength

  • 10.1. 10 mg
  • 10.2. 25 mg

11. SGLT2 Inhibitors Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. SGLT2 Inhibitors Treatment Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare Patients
  • 12.3. Hospitals

13. SGLT2 Inhibitors Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. SGLT2 Inhibitors Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. SGLT2 Inhibitors Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States SGLT2 Inhibitors Treatment Market

17. China SGLT2 Inhibitors Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca PLC
  • 18.6. Boehringer Ingelheim International GmbH
  • 18.7. Cipla Limited
  • 18.8. Dr. Reddy's Laboratories Limited
  • 18.9. Eli Lilly and Company
  • 18.10. Johnson & Johnson
  • 18.11. Merck & Co., Inc.
  • 18.12. Mylan N.V.
  • 18.13. Pfizer Inc.
  • 18.14. Sun Pharmaceutical Industries Ltd.
  • 18.15. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 10 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 10 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 10 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 25 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 25 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 25 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOMECARE PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOMECARE PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOMECARE PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 136. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)